Colorectal cancer metastatic
RecruitingStudy on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy
Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy
- Disease:Colorectal cancer metastatic
- Substances:CapecitabineRegorafenib+2
France- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Centre Hospitalier Regional Universitaire







